Patent ID: 8980259
Filing Date: 2015-03-17
Classification: A61K,A61P,C07K

Abstract:
1. A method for treating cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of: a) the alpha-isoform specific phosphatidylinositol 3-kinase (PI3K) inhibitor (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide) (COMPOUND A) or a pharmaceutically acceptable salt thereof; and b) an insulin-like growth factor-1 receptor (IGF1R) inhibitor which is an antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises a variable region comprising the complementarity determining region (CDR) amino acid sequences set forth in SEQ ID NOs: 5, 6, and 7, and wherein the light chain comprises a variable region comprising the CDR amino acid sequences set forth in SEQ ID NOs: 8, 9, and 10; and wherein the cancer is ovarian cancer or breast cancer.